Pyxis oncology stock prediction.

Based on Pyxis Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $38 thousand and a GAAP net loss of $19.24 million.As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on ...Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of ...Real time Pyxis Oncology (PYXS) stock price quote, stock graph, news & analysis. Pyxis Oncology, Inc. is a multi-asset, multi-modality company focused on defeating difficult to treat cancers and improve patient lives. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics.

On average, Wall Street analysts predict. that Pyxis Oncology's share price could reach $8.67 by Nov 30, 2024. The average Pyxis Oncology stock price prediction forecasts a potential upside of 445.09% from the current PYXS share price of $1.59. Mar 30, 2023 · Pfizer-backed Pyxis hits 52-week high to cross $200M market cap. Pyxis Oncology ( NASDAQ: PYXS) shares reached a new 52-week high as the clinical-stage biotech backed by pharma giant Pfizer ( PFE ... Feb 13, 2023 · As of February 13, 2023, the average one-year price target for Pyxis Oncology is $11.22. The forecasts range from a low of $4.04 to a high of $16.80. The average price target represents an ...

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation …

Cash runway extended into first half 2025. CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, announced today that it has received clearance for its two Investigational New …Pyxis Oncology Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-1.997 per share for the current fiscal year. Pyxis Oncology Inc does not currently pay a dividend.On September 13, 2023, Lara Sullivan, President and CEO of Pyxis Oncology Inc (NASDAQ:PYXS), sold 27,917 shares of the company. Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history ...Pyxis Oncology Inc (NASDAQ: PYXS) agreed to acquire Apexigen Inc (NASDAQ: APGN) in an all-stock transaction for an implied value of $0.64 per Apexigen share. Apexigen went public in a blank-check ...Fundamentals. 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. Track Pyxis Oncology Inc (PYXS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.

As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination ...

7 พ.ย. 2566 ... As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. ... predict all risk factors, nor ...

Stock Price Forecast. According to 3 stock analysts, the average 12-month stock price forecast for Pyxis Oncology stock is $12, which predicts an increase of …Nov 30, 2023 · High Growth Earnings: PYXS is forecast to remain unprofitable over the next 3 years. Revenue vs Market: PYXS's revenue (66.6% per year) is forecast to grow faster than the US market (8.1% per year). High Growth Revenue: PYXS's revenue (66.6% per year) is forecast to grow faster than 20% per year. It has developed a portfolio that includes antibody drug conjugate (ADC), product candidates, immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Its product pipelines include PYX-201, PYX-106 and …BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four different assets have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th …Pyxis Oncology Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time PYXS stock price.FIRST REPUBLIC BANK Common Stock. $13.33 UNCH. Apple Inc. Common Stock. NVDA. NVIDIA Corporation Common Stock. $264.68 UNCH. Find the latest dividend history for Pyxis Oncology, Inc. Common Stock ...US7473241013. Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies ...

— Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit developed by Pfizer — CAMBRIDGE, Mass., March 18, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the …Pyxis Oncology (NASDAQ: PYXS) is owned by 16.78% institutional shareholders, 46.08% Pyxis Oncology insiders, and 37.14% retail investors. Pfizer Inc is the largest individual Pyxis Oncology shareholder, owning 7.03M shares representing 15.87% of the company. Pfizer Inc's Pyxis Oncology shares are currently valued at $10.62M.As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...Pfizer will receive an undisclosed upfront payment from Pyxis for the license to PYX-201, an ADC that targets a novel tumor-restricted antigen in certain solid tumors, and PYX-203, a DNA damaging agent that targets a well-validated tumor antigen expressed in some blood cancers. Pyxis did not disclose the specific antigens targeted.Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, …

As of February 13, 2023, the average one-year price target for Pyxis Oncology is $11.22. The forecasts range from a low of $4.04 to a high of $16.80. The average price target represents an ...

The stock options have a ten-year term and an exercise price of $4.01, the closing price of Pyxis Oncology’s common stock as reported by Nasdaq on March 31, 2023. Pyxis Oncology is providing ...Pyxis Announces Pricing of Upsized Initial Public Offering. (GlobeNewswire) Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly ...US7473241013. Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies ...In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), with a price target of $9.00.The company’s shares opened today ...Valuation metrics show that Pyxis Oncology, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of PYXS ...Find the latest Pyxis Oncology, Inc. (PYXS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.US7473241013. Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies ...Pyxis Oncology stock was originally listed at a price of $13.20 in Oct 8, 2021. If you had invested in Pyxis Oncology stock at $13.20, your return over the last 2 years would have been -86.82%, for an annualized return of -63.69% (not including any dividends or dividend reinvestments).Dec 1, 2023 · According to analysts, Pyxis Oncology's stock has a predicted upside of 311.52% based on their 12-month stock forecasts. What analysts cover Pyxis Oncology? Pyxis Oncology has been rated by HC Wainwright , Royal Bank of Canada , and William Blair in the past 90 days. Pyxis Oncology, Inc NASDAQ: PYXS is a preclinical oncology company focused on developing a range of therapeutics to treat cancers. The Company has developed ...

Pyxis Oncology, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 83-1160910 (State or other jurisdiction of incorporation or organization) ... Common Stock, par value $0.0001 per share 9,591,000 $16.00 $153,456,000 $15,865.37 (1) ...

RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS) with an Outperform rating and a price target of...

PYXS Earnings Date and Information. Pyxis Oncology last announced its earnings results on November 7th, 2023. The reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. Pyxis Oncology has generated ($2.55) earnings per share over the last year ( ($2.55) diluted earnings per share).Get the latest Pyxis Oncology Inc (PYXS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. High Growth Earnings: PYXS is forecast to remain unprofitable over the next 3 years. Revenue vs Market: PYXS's revenue (66.6% per year) is forecast to grow faster than the US market (8.1% per year). High Growth Revenue: PYXS's revenue (66.6% per year) is forecast to grow faster than 20% per year.According to CBS News, Harry Dent’s predictions in his books have never been right. His most accurate prediction was from his 1993 book; he predicted that the stock market would rise substantially, but he was a year early with his predictio...Real time Pyxis Oncology (PYXS) stock price quote, stock graph, news & analysis.May 30, 2023 at 5:30 AM · 6 min read. Pyxis Oncology. First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate. Second dose level initiated in Phase 1 trial ...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Stock Price Forecast. According to 3 stock analysts, the average 12-month stock price forecast for Pyxis Oncology stock is $12, which predicts an increase of …According to analysts, Pyxis Oncology's stock has a predicted upside of 311.52% based on their 12-month stock forecasts. What analysts cover Pyxis …Cash runway extended into first half 2025. CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, announced today that it has received clearance for its two Investigational New …

As of March 25, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,841,747. Conference Call and Webcast Details. Pyxis Oncology management will host a conference call and live webcast on Tuesday, March 29, 2022, at 8:00 a.m. ET to discuss recent corporate updates. The live call can be accessed by dialing (833) 945 ...Fundamentals There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Latest 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or …On average, Wall Street analysts predict that Pyxis Oncology 's share price could reach $11.00 by Sep 5, 2024. The average Pyxis Oncology stock price prediction forecasts …Instagram:https://instagram. nyse tlsazerodha apppbr dividendscandle graph Find the latest Oncology Pharma Inc. (ONPH) stock quote, history, news and other vital information to help you with your stock trading and investing. 5 year u.s. treasury yieldbest health insurance companies virginia Pyxis Oncology, Inc. Stock Prediction and Forecast [PYXS] PYXS price prediction was made on Thursday, March 30, 2023. ️ Check the most recent PYXS analysis at ... desktop metals stock Mar 31, 2023 · The stock options have a ten-year term and an exercise price of $4.01, the closing price of Pyxis Oncology’s common stock as reported by Nasdaq on March 31, 2023. Astellas Pharma Inc. -4.37%. ¥3.42T. PYXS | Complete Pyxis Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.According to CBS News, Harry Dent’s predictions in his books have never been right. His most accurate prediction was from his 1993 book; he predicted that the stock market would rise substantially, but he was a year early with his predictio...